Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy 1 . However, the efficacy of kinase inhibitors in patients whose tumours harbour such alleles is invariably limited by innate or acquired drug resistance 2, 3 . The identification of resistance mechanisms has revealed a recurrent theme-the engagement of survival signals redundant to those transduced by the targeted kinase 4 . Cancer cells typically express multiple receptor tyrosine kinases (RTKs) that mediate signals that converge on common critical downstream cell-survival effectors-most notably, phosphatidylinositol-3-OH kinase (PI(3)K) and mitogen-activated protein kinase (MAPK) 5 . Consequently, an increase in RTK-ligand levels, through autocrine tumour-cell production, paracrine contribution from tumour stroma 6 or systemic production, could confer resistance to inhibitors of an oncogenic kinase with a similar signalling output. Here, using a panel of kinase-'addicted' human cancer cell lines, we found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands. Among the findings with clinical implications was the observation that hepatocyte growth factor (HGF) confers resistance to the BRAF inhibitor PLX4032 (vemurafenib) in BRAF-mutant melanoma cells. These observations highlight the extensive redundancy of RTK-transduced signalling in cancer cells and the potentially broad role of widely expressed RTK ligands in innate and acquired resistance to drugs targeting oncogenic kinases.
Using 41 human-tumour-derived cell lines with previously defined kinase dependency [7] [8] [9] , we undertook a 'matrix analysis' to examine the effects of six different RTK ligands known to be widely expressed in tumours 10 (HGF, epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), neuregulin 1 (NRG1) and insulin-like growth factor (IGF)) on drug response. We quantified the effect of exposing these cell lines to each ligand on the half-maximum inhibitory concentration (IC 50 ) for a kinase inhibitor that otherwise potently suppresses their growth ( Supplementary Fig. 1a ). Nearly all of the cell lines tested, representing multiple tissue types and distinct kinase dependencies, could be rescued from drug-induced growth inhibition by one or more RTK ligands (Fig. 1a) .
The consequences of ligand exposure on drug response were categorized as follows: (1) 'no rescue', addition of ligand did not affect drug response; (2) 'partial rescue', ligand partially abrogated treatment response; or (3) 'complete rescue', ligand 'right-shifted' the IC 50 curve .10-fold, or completely suppressed drug response (Fig. 1b) . HGF, FGF and NRG1 were the most broadly active ligands, followed by EGF, whereas IGF and PDGF had relatively little effect, despite activating their corresponding receptors (Supplementary Figs 1b and  5a cells from cisplatin sensitivity, suggesting that RTK ligands do not confer broad protection from toxic agents ( Supplementary Fig. 1c ).
To explore the signalling dynamics associated with ligand-mediated rescue, we assessed the status of two downstream survival signalling pathways commonly engaged by RTKs: the PI(3)K-AKT and MAPK pathways 11 . Where ligand-mediated rescue was achieved, ligand re-activated at least one of these pathways despite the presence of drug (Fig. 2a) . Pathway re-activation was not due to re-activation of the oncogenic kinase, as kinase autophosphorylation remained suppressed after ligand co-treatment. In the tested models, HGF re-activated both PI(3)K and MAPK, IGF and NRG1 only re-activated PI(3)K and FGF, and EGF only re-activated MAPK. Activation of the 'redundant RTK' and consequent downstream survival signalling persisted for at least 48 h ( Supplementary Fig. 1d ). A functional role for re-activation of both PI(3)K and MAPK signalling was observed in lapatinib-treated AU565 cells in the presence of NRG1, FGF or a combination ( Supplementary Fig. 2a ). However, specifically inhibiting PI(3)K attenuated HGF-promoted drug resistance, which was associated with engagement of both survival pathways (Supplementary Fig. 2b ). As expected, ligand rescue was blocked by co-targeting the secondary activated kinase, confirming that effective ligands were acting via their cognate RTKs (Fig. 2b , c and Supplementary Fig. 3a , b). Inhibitors of the 'secondary' RTK that mediated ligand rescue had little or no effect as single agents, indicating that the kinase-addicted cells are not initially dependent on multiple different RTKs in the absence of available ligand. Moreover, ligand stimulation had little or no effect on cell proliferation (Figs 1b and 2b) .
Analysis of baseline RTK expression confirmed that the tested lines express multiple RTKs. Ligand-induced rescue was well correlated with expression of certain RTKs in some cases ( Supplementary Fig. 4) , suggesting that the RTK profile of tumours before treatment could inform an optimal treatment strategy that anticipates the need to co-target two or more kinases. In some cases, ligands were unable to rescue cells from drug effects despite expression of the corresponding RTK. In a few cases, the RTK ligand activated its receptor; however, engagement of PI(3)K or MAPK was not observed ( Supplementary  Fig. 5a ). In other cases, the ligand activated its receptor as well as at least one downstream effector; however, that was not sufficient for rescue ( Supplementary Fig. 5b, c) . This was observed, for example, with H2228 and H358 cells exposed to HGF, or with COLO-201 cells exposed to NRG1. However, H2228 and H358 cells are rescued by HGF after longer-term drug treatment, implicating the presence of a subpopulation of HGF-responsive cells selected over time in the presence of an inhibitory kinase ( Supplementary Fig. 6c, d ).
There were several findings with clinical implications. For example, one of two tested non-small-cell lung carcinoma (NSCLC) cell lines harbouring an anaplastic lymphoma kinase (ALK) translocation (NCI-H3122 cell line), and exhibiting ALK addiction, was rescued Fig. 6a, b) . In these HGF receptor (MET)-expressing cells, HGF activates extracellular signal-regulated kinase (ERK) and AKT even in the presence of the ALK-selective inhibitor TAE684. In contrast, survival of these cells was disrupted even in the presence of HGF by crizotinib, a dual ALK/MET kinase inhibitor approved for treatment of ALK-translocated NSCLCs 12 . The second ALK-translocated NSCLC line, NCI-H2228, also expresses MET, but was not rescued from ALK inhibition by HGF at the 72-h time point. However, HGF re-activated AKT and ERK in the presence of TAE684 ( Supplementary  Fig. 5b) , and longer-term TAE684 treatment in the presence of HGF yielded TAE684-resistant cells (Supplementary Fig. 6c) . The relatively durable clinical responses observed in ALK-translocated NSCLC patients might be attributed in part to the dual ALK/MET inhibitory activity of crizotinib.
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The ability of HGF to rescue three of nine tested human epidermal growth factor receptor 2 (HER2)-amplified breast cancer cell lines from growth inhibition by the HER2 kinase inhibitor lapatinib was also unexpected (Fig. 3a, b) . These three cell lines express MET, which was correlated with the ability of HGF to attenuate lapatinib response (Fig. 3b) . As with NCI-H228 cells, longer-term co-treatment (12 days) of the partially HGF-rescued AU565 cells revealed that HGF rapidly promoted lapatinib resistance, potentially by driving selection of a subpopulation of MET-expressing cells (Fig. 3c) . Indeed, 9-day lapatinib/HGF co-treatment yielded a population of cells with increased MET (Supplementary Fig. 7a ). HGF re-activated PI(3)K and MAPK signalling specifically in MET-positive cells (Fig. 3d) .
A subset of tested HER2-positive primary breast tumours express MET protein (Supplementary Fig. 7b ). One HER2-amplified breast cancer cell line (HCC1954) showed elevated phospho-MET in the absence of exogenous HGF, implicating an autocrine mechanism (Fig. 3b) , and MET inhibition in these cells delayed the emergence of lapatinib resistance (Fig. 3e) . Collectively, these results suggest that MET-expressing HER2-positive breast tumours might evade HER2 inhibition by engaging MET in a subpopulation of 'primed' tumour cells, depending on the availability of HGF. Additionally, eight of nine tested HER2-amplified breast cell lines were rescued from lapatinib sensitivity by exposure to the HER3 ligand NRG1 (Fig. 1a and Supplementary Fig. 7c ), possibly implicating NRG1 levels in the tumour microenvironment in the variable response to HER2 kinase inhibition.
Another observation with clinical implications was the unexpected finding that HGF attenuated the response to the BRAF kinase inhibitor PLX4032 (vemurafenib) in BRAF-mutant cell lines. PLX4032 recently demonstrated remarkable efficacy in BRAF-mutant melanoma, leading to clinical approval 13 . Notably, among 446 tested secreted factors, HGF was among a very small number that could rescue BRAF-mutant melanoma cells from PLX4032 sensitivity (Supplementary Fig. 8 ).
Among 12 additional BRAF-mutant melanoma cell lines tested, HGF significantly attenuated PLX4032 sensitivity in 5 lines (Fig. 4a) . Eight of ten HGF-rescued cell lines expressed detectable MET, whereas MET was undetectable or barely detectable in the non-rescued cells. MET expression was correlated with HGF rescue (Fig. 4a) , and HGF re-activated MAPK in lines rescued by HGF, but not in MET-negative HGF-non-rescued cells (Fig. 4b) . As anticipated, rescue by HGF was blocked when MET was inhibited by crizotinib ( Fig. 4b and Supplementary Fig. 9a ). One BRAF-mutant cell line (624MEL) showed elevated phospho-MET in the absence of exogenous HGF, consistent with an autocrine mechanism (Fig. 4a) , and MET inhibition in these cells delayed PLX4032 resistance (Supplementary Fig. 9b ). Crizotinib co-treatment also prevented resistance to PLX4032 in two cell lines (A375 and 928MEL) with undetectable phospho-MET, further supporting a role for HGF-activated MET in PLX4032 resistance ( Supplementary Fig. 9b ).
To confirm these findings in vivo, we performed xenograft studies with BRAF-mutant 928MEL and 624MEL melanoma cells. Activation of MET in tumours using the MET-agonistic antibody 3D6 strongly abrogated the growth-suppressive effects of PLX4032 (Fig. 4c) . The relevance of MET activation by 3D6 in attenuating the PLX4032 response was verified by co-treating with a MET kinase inhibitor. Inhibiting MET enhanced the effect of PLX4032 on tumour regression (Fig. 4c) , with more partial responses observed in the 928MEL model ( Supplementary Fig. 10 ).
To extend these findings in a clinical context, we tested the hypothesis that circulating HGF in BRAF-mutant melanoma patients could contribute to clinical outcome. Pre-treatment plasma HGF levels were 
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measured from 126 of the 132 patients enrolled onto the BRIM2 clinical trial (BRAF-mutant metastatic melanoma patients treated with PLX4032). HGF levels ranged from 33-7,200 pg ml 21 with a median level of 334 pg ml 21 ( Supplementary Fig. 11a ). Increased plasma HGF was associated with worse outcome as measured by progression-free survival (PFS; hazard ratio, 1.42; P , 0.005) and overall survival (OS; hazard ratio, 1.8; P , 0.001; Fig. 4d, e) . Segregating patients into tertiles revealed a continuous relationship between HGF level and outcome, rather than a threshold effect (Supplementary Fig. 11b ). As BRIM2 was a single-arm study in which all patients received PLX4032, it is not possible to determine whether higher HGF levels confer drug resistance; however, this study implicates HGF-MET signalling in disease progression and overall survival, and together with related findings 14 , suggests a potential role for HGF in the response to BRAF inhibition in BRAF-mutant melanoma.
Overall, the findings highlight the extensive nature of signal crosstalk among RTKs that are co-expressed in most tumour cells, and the potentially broad role of RTK ligands in innate and acquired resistance to kinase inhibitors. Such ligands could be produced by tumour cells themselves to drive autocrine survival mechanisms, by tumour stroma, or systemically to affect drug response 15, 16 . The increasingly appreciated heterogeneity of human tumours complicates the elucidation of drug resistance mechanisms [17] [18] [19] . In the context of our findings, we imagine distinct mechanisms by which such heterogeneity could contribute to acquired resistance. Thus, a subpopulation of tumour cells present before therapy capable of responding to a survival-promoting RTK ligand might be expanded through the selective pressure of drug treatment if such a ligand becomes available within the tumour microenvironment. Indeed, analysis of MET expression in BRAF-mutant melanoma cells revealed a heterogeneous cell population (Supplementary Fig. 12 ). Similarly, in EGFR-mutant NSCLC, a subpopulation of MET-driven tumour cells may emerge upon exposure to HGF during EGFR tyrosine kinase inhibitor treatment 20 . Activation of multiple RTKs has been reported in glioblastoma, and suppression of pro-survival signals and consequent cell death was only observed after co-targeting multiple 
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. A subpopulation of RTK-ligand-producing tumour cells may be selected during treatment. In various pre-clinical models, the observed acquired resistance mechanism involved a 'switch' to a new RTK dependency [22] [23] [24] [25] [26] [27] , which in some cases could be attributed to increased RTK-ligand production.
Although genomic biomarkers have been critical in identifying the patients most likely to benefit from therapy, there is a largely unexplained wide range of clinical benefit among such patients in terms of magnitude and duration of response 12, 13 . Our findings support a potentially broad role for RTK ligands in the overall clinical benefit from such therapies, and provide a foundation for the use of biomarkers based on the expression of RTKs and their ligands to inform treatment strategies that anticipate both innate and acquired resistance mechanisms.
METHODS SUMMARY
RTK-ligand matrix screen. Cell viability was assessed using the nucleic acid stain Syto 60 (Invitrogen). Cells (3,000-5,000 per well) were seeded into 96-well plates. The next day, cells were treated with (or without) 50 ng ml 21 RTK ligand and concomitantly exposed to increasing concentrations of the relevant kinase inhibitor. After 72 h, cells were fixed in 4% formaldehyde, stained with Syto 60 and cell number was assessed using an Odyssey scanner (Li-Cor). Cell viability was calculated by dividing the fluorescence from the drug-treated cells by the fluorescence from the control (no drug) treated cells.
